Search
MDX-214
go.drugbank.com/drugs/DB06110ExperimentalMDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector
N-(2-Aminoethyl)-1-aziridineethanamine
go.drugbank.com/drugs/DB15643ExperimentalFirst described in the literature in 2004, N-(2-Aminoethyl)-1-aziridineethanamine is an experimental angiotensin converting enzyme 2 inhibitor investigated for its use in treating cardiovascular disease
SL017
go.drugbank.com/drugs/DB05156ExperimentalSL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis
TC-5231
go.drugbank.com/drugs/DB05333ExperimentalTC-5231 is mecamylamine hydrochloride, the active ingredient in FDA-approved product, Inversine, but in a lower dose than Inversine. … TC-5231 is a small molecule that has been under investigation as an oral treatment for ADHD (Attention Deficit/Hyperactivity Disorder).
Gadoteric acid
go.drugbank.com/drugs/DB09132ApprovedInvestigational[A263141,A263106] Gadoterate is approved by the FDA under the brand name DOTAREM on 20th March 2013 for intravenous uses with magnetic resonance imaging (MRI) in the brain (intracranial), spine, and
Urofollitropin
go.drugbank.com/drugs/DB00094ApprovedVet approvedWithdrawnUrofollitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).
Alvocidib
go.drugbank.com/drugs/DB03496InvestigationalIt works by inhibiting cyclin-dependent kinases, arresting cell division and causing apoptosis in non-small lung cancer cells. … Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer.
Azelnidipine
go.drugbank.com/drugs/DB09230InvestigationalIt is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan.
Zavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigationalDue to its pharmacological properties, it can be administered intranasally. … In migraine, CGRP innervates pain-producing meningeal blood vessels and is released by trigeminal nerve stimulation.